Federal Circuit Rejects Novartis’ Bid To Issue Mandate In Drug Patent Row
WASHINGTON, D.C. — A panel in the Federal Circuit U.S. Court of Appeals on Jan. 14 denied Novartis Pharmaceuticals Corp.’s motion to expedite the issuance of its mandate after finding only...To view the full article, register now.
Already a subscriber? Click here to view full article